CA2819554A1 - Dosage and administration of bispecific scfv conjugates - Google Patents
Dosage and administration of bispecific scfv conjugates Download PDFInfo
- Publication number
- CA2819554A1 CA2819554A1 CA2819554A CA2819554A CA2819554A1 CA 2819554 A1 CA2819554 A1 CA 2819554A1 CA 2819554 A CA2819554 A CA 2819554A CA 2819554 A CA2819554 A CA 2819554A CA 2819554 A1 CA2819554 A1 CA 2819554A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- composition
- intervals
- days
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42199210P | 2010-12-10 | 2010-12-10 | |
| US61/421,992 | 2010-12-10 | ||
| PCT/US2011/064496 WO2012079093A2 (en) | 2010-12-10 | 2011-12-12 | Dosage and administration of bispecific scfv conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2819554A1 true CA2819554A1 (en) | 2012-06-14 |
Family
ID=46207797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2819554A Abandoned CA2819554A1 (en) | 2010-12-10 | 2011-12-12 | Dosage and administration of bispecific scfv conjugates |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140017264A1 (OSRAM) |
| EP (1) | EP2648753A4 (OSRAM) |
| JP (1) | JP2014500278A (OSRAM) |
| AU (1) | AU2011341337A1 (OSRAM) |
| CA (1) | CA2819554A1 (OSRAM) |
| WO (1) | WO2012079093A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0808055A2 (pt) | 2007-02-16 | 2013-07-30 | Merrimack Pharmaceuticals Inc | anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, composiÇço, Ácido nucleico isolado, vetor de expressço, cÉlula hospedeira, hibridoma, kit, uso de um anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, mÉtodo para diagnosticar um cÂncer associado com erbb3 em um paciente, e, anticorpo |
| PL2544680T3 (pl) | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego |
| EP2566892B1 (en) | 2010-05-06 | 2017-12-20 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
| CA2798390A1 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
| AU2012222094A1 (en) * | 2011-02-24 | 2013-10-10 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-ErbB3 agents |
| EP3290442A1 (en) | 2011-11-04 | 2018-03-07 | Novartis AG | Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs |
| EP2847226A4 (en) * | 2012-05-11 | 2016-05-11 | Merrimack Pharmaceuticals Inc | DOSAGE AND ADMINISTRATION OF BIS SPECIFIC SCFV CONJUGATES IN COMBINATION WITH ANTICROBIAL AGENTS |
| US9345766B2 (en) | 2012-08-30 | 2016-05-24 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-ERBB3 agents |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US20160045596A1 (en) | 2014-08-05 | 2016-02-18 | Merrimack Pharmaceuticals, Inc. | Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090226429A1 (en) * | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
| EA022201B1 (ru) * | 2008-04-11 | 2015-11-30 | Мерримак Фармасьютикалз, Инк. | Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение |
-
2011
- 2011-12-12 US US13/992,460 patent/US20140017264A1/en not_active Abandoned
- 2011-12-12 WO PCT/US2011/064496 patent/WO2012079093A2/en not_active Ceased
- 2011-12-12 AU AU2011341337A patent/AU2011341337A1/en not_active Abandoned
- 2011-12-12 EP EP11847515.1A patent/EP2648753A4/en not_active Withdrawn
- 2011-12-12 CA CA2819554A patent/CA2819554A1/en not_active Abandoned
- 2011-12-12 JP JP2013543410A patent/JP2014500278A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011341337A1 (en) | 2013-06-13 |
| EP2648753A4 (en) | 2015-06-24 |
| JP2014500278A (ja) | 2014-01-09 |
| WO2012079093A3 (en) | 2013-08-08 |
| US20140017264A1 (en) | 2014-01-16 |
| EP2648753A2 (en) | 2013-10-16 |
| WO2012079093A2 (en) | 2012-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140017264A1 (en) | Dosage and administration of bispecific scfv conjugates | |
| JP6283665B2 (ja) | Ｇｄ２陽性癌を治療するための方法 | |
| US20060171946A1 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
| TWI513465B (zh) | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 | |
| JP2004527456A (ja) | Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療 | |
| TW201834687A (zh) | 抗-cd19類美登醇(maytansinoid )免疫結合物抗體於治療b-細胞惡性症狀之用途 | |
| EP3042669A1 (en) | Antitumor agent and antitumor effect enhancer | |
| JP6488273B2 (ja) | 前立腺癌治療のための抗アルファ−ｖインテグリン抗体 | |
| JP6722688B2 (ja) | 医薬組成物、調製及びその使用 | |
| US20050112061A1 (en) | Use of a VEGF antagonist in combination with radiation therapy | |
| RU2011146339A (ru) | Комбинированная терапия с использованием агента (ов) против igfr и специфических ингибиторов igf-1r | |
| CN118806923A (zh) | 西妥昔单抗-ir700偶联物组合物 | |
| US20230001006A1 (en) | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers | |
| AU2005325227B2 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
| WO2019238713A2 (en) | Treatments etc | |
| US20200093789A1 (en) | Cancer Treatment with a CXCL12 Signaling Inhibitor and an Immune Checkpoint Inhibitor | |
| JP2023549464A (ja) | Ｂ細胞免疫寛容の誘導及びｍＩｇＭ陽性発現Ｂ細胞リンパ腫の標的化における葉酸及び葉酸修飾の使用 | |
| TW202116802A (zh) | 治療眼部疾病之方法 | |
| CN119255817A (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| US20250381268A1 (en) | Pharmaceutical composition comprising anti-ctla4 and anti-pd1 antibody mixture and therapeutic use thereof | |
| WO2023160517A1 (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| KR20210106197A (ko) | EGFR과 Her2 발현 암세포를 타겟으로 하는 항체-약물 중합체 개발 | |
| CN118946366A (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| EP4548929A1 (en) | Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof | |
| JP2024037356A (ja) | 医薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20161214 |
|
| FZDE | Discontinued |
Effective date: 20161214 |